COVID-19

These bivalent formulations include an mRNA component common to the BA.4 and BA.5 Omicron variant.

Using electronic medical record data from 2018-2020 obtained from 24 medical centers across the US, including Johns Hopkins, University of Colorado, and Mayo Clinic institutions, a new study suggests rates of youth onset type 2 diabetes increased 77% during the first year of the pandemic.

What are the long term psychiatric and neuropsychiatric complications of COVID-19?

With the evolution of different COVID-19 variants, finding the mean incubation period has become more complex.

Pfizer-BioNTech hopes booster can be available for use this fall.

The vaccine was previously authorized under an EUA for adults aged 18 and older.

The quest to understand what leads to long COVID continues, with a new cross-sectional study, considered one of best on long COVID so far.

Studies tie disease to higher risk of COVID-related hospitalizations and deaths

The latest guidance for when to administer the COVID-19 vaccine to patients aged 6 months and older.

Adults aged 18 and older are eligible to receive the vaccine.

Groups responded quickly in defense of pharmacists’ ability to prescribe Paxlovid through Test to Treat programs.

The risk of breakthrough was higher in people living with HIV regardless of CD4 count or HIV viral suppression, according to findings reported by researchers at Johns Hopkins.

According to the agency, this new authority may improve access to patients at high risk for severe COVID-19.

Purchase follows FDA recommendation to include Omicron component in boosters.

Epic research suggests that like COVID-19, flu and other viral pneumonias can result in long-term symptoms like fatigue and brain fog. Why that might be is open question.

Recent research has shown less than 1% of patients at high risk for experiencing severe COVID-19 who were treated with Paxlovid (nirmatrelvir and ritonavir) experienced a second bout of COVID-19.

Monoclonal antibodies have been helpful in preventing severe illness in patients at increased risk, but barriers to receiving this therapy exist.

A majority of survey respondents were willing to receive a COVID-19 vaccine.

Staying abreast of current data on the condition is vital.

If authorized, it will be the fourth COVID-19 vaccine available in the Untied States.

Results address the concern that COVID-19 vaccination might not be effective among those living with HIV.

Research suggests that COVID-19 vaccination may serve a therapeutic effect, possibly reducing the risk of developing long COVID when administered to those currently infected.

Communities who are undeserved and vulnerable to COVID-19 were found to be not have much-needed access to test-to-treat location, according to an analysis by the American Pharmacists Association.

The test will be available direct to consumers without a prescription.

Children may receive a single booster shot at least 5 months after completing their initial Pfizer-BioNTech 2-dose series.